Two novel basiliskamide antibacterial compounds, their preparation methods, and their application in controlling Phytophthora downyensis on litchi.
By isolating and identifying compounds L53 and L56 from the fermentation products of salt-tolerant Bacillus brevis T101, the problem of controlling downy mildew of litchi was solved by utilizing multiple antibacterial mechanisms. This achieved highly efficient inhibition of downy mildew of litchi and broad-spectrum inhibition of a variety of plant pathogens, providing a prospect for the industrial application of green pesticides.
Patent Information
- Application Number
- CN202611405042.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-10
- Publication Date
- 2026-11-17
AI Technical Summary
There is a lack of novel, highly active, and clearly defined biological antibacterial substances in the current technology for the prevention and control of lychee downy mildew. Chemical fungicides have led to frequent occurrences of pathogen resistance, excessive pesticide residues, and serious environmental pollution.
Two novel monomeric compounds, 2E-Basiliskamide B and Basiliskamide C, were isolated and identified from the fermentation metabolites of Brevibacillus halotolerans T101. They exert antibacterial effects by disrupting the integrity of the pathogen's plasma membrane, inducing intracellular electrolyte leakage, reducing intracellular ATP content, and inhibiting hyphal respiration and metabolism.
Compound L53 exhibits a 74.67% mycelial growth inhibition rate against Phytophthora litchii, while L56 demonstrates broad-spectrum antibacterial activity against a variety of plant pathogens, providing an effective means for green control of Phytophthora litchii and overcoming the shortcomings of existing technologies.
Smart Images

Figure CN123106465A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of natural organic compounds and biopesticides, specifically to two novel antibacterial compounds, 2E-Basiliskamide B (L53) and Basiliskamide C (L56), their preparation methods, and their specific applications in the prevention and control of lychee downy mildew. Background Technology
[0002] Lychee downy mildew is caused by Phytophthora lycheeii (Phytophthora infestans). Peronophythora litchii This devastating disease of lychee can cause massive fruit drop and rot, severely hindering the development of the lychee industry. Currently, production mainly relies on chemical fungicides for control. However, long-term use of these pesticides has led to frequent occurrences of pathogen resistance, excessive pesticide residues, and environmental pollution. There is an urgent need to develop highly efficient, low-toxicity, and environmentally friendly biological antibacterial substances.
[0003] Natural antibacterial compounds are core leading resources for the development of green pesticides, possessing irreplaceable advantages in the green control of plant diseases. Currently, the chemical structures of compounds 2E-Basiliskamide B and Basiliskamide C have not been publicly reported, nor are there any studies or applications of using these two compounds to inhibit *Phytophthora litchi*. Current bio-based antibacterial substances used to control *Phytophthora litchi* generally suffer from weaknesses such as weak antibacterial activity, unclear mechanisms of action, and a lack of novel lead compounds. Therefore, there is an urgent need to explore novel antibacterial lead compounds with novel structures, excellent activity, and clearly defined mechanisms of action.
[0004] Based on the above situation, the present invention... Brevibacillus halotolerans Two novel monomeric compounds were isolated and identified from the fermentation metabolites of T101. E Basiliskamide B and Basiliskamide C. Systematic bioactivity verification and antibacterial mechanism investigation confirmed that both compounds have a strong inhibitory effect on *Phytophthora litchii*, with a clear pathway of action. Simultaneously, both also exhibit varying degrees of antibacterial activity against a variety of plant pathogenic fungi and bacteria, demonstrating their potential as green biological pesticides for the control of *Phytophthora litchii*. Summary of the Invention
[0005] The purpose of this invention is to provide two novel antibacterial compounds 2 EBasiliskamide B (L53) and Basiliskamide C (L56), along with their preparation methods and antibacterial applications, are the first-time discoveries of these two novel natural structural products. They exhibit strong inhibitory activity against *Phytophthora lichei* mycelial growth and sporangium germination, with a clear mechanism of action and outstanding antibacterial effect. Furthermore, both compounds possess differentiated broad-spectrum antibacterial activity, capable of inhibiting various plant pathogenic fungi and bacteria, and are primarily suitable for the green control of *Phytophthora lichei* downy mildew.
[0006] The first objective of this invention is to provide novel structural natural compounds L53 and L56, and their application in the prevention and control of plant diseases, the structures of which are shown in formulas (I) and (II): .
[0007] Preferably, the application for preventing and controlling plant diseases specifically refers to preventing and controlling litchi downy mildew caused by Phytophthora indicum.
[0008] The second objective of this invention is to provide methods for preparing the new compounds L53 and L56. Both of these new compounds were isolated from salt-tolerant Bacillus brevis (…). Brevibacillus halotolerans Fermentation culture of T101.
[0009] Preferably, the method for preparing the new compound includes the following steps:
[0010] (1) To Brevibacillus halotolerans T101 was subjected to liquid fermentation culture, and the fermentation broth was collected;
[0011] (2) The fermentation broth was enriched using macroporous resin to obtain total metabolic extract;
[0012] (3) The extract was purified by silica gel column chromatography and reversed-phase high performance liquid chromatography to obtain monomeric compounds L53 or L56 respectively.
[0013] Preferably, the method for preparing the new compound specifically includes the following steps:
[0014] (1) Preparation of salt-tolerant short-spore bacteria ( Bacillus halotolerans The liquid fermentation culture of T101 was enriched and filtered using macroporous adsorption resin XAD-16. After drying, the macroporous resin was added to 8-12 times its volume of methanol solution and extracted by shaking in a shaker at 180-220 rpm for 20-30 h. The extract was then concentrated to obtain a crude extract.
[0015] (2) The crude extract was subjected to gradient elution by forward silica gel column chromatography, with petroleum ether-ethyl acetate volume ratios of 10:1, 5:1, 2:1, 1:1, 1:2, 0:1, ethyl acetate-methanol volume ratios of 30:1, 20:1, 15:1, 10:1, 5:1, 0:1, and pure methanol as the elution system. The volume of solvent used for each gradient elution was 2-3 L. The eluted fractions were collected, concentrated by rotary evaporation, and reconstituted with methanol. The fractions were analyzed by thin-layer chromatography (TLC) and the same fractions were combined. The ethyl acetate-methanol (15:1) eluted fraction was named Fr.D. Fraction Fr.D was initially separated by semi-preparative high-performance liquid chromatography (SHPLC). The chromatographic conditions were: YMC semi-preparative column, mobile phase of 49% acetonitrile aqueous solution containing 0.001% formic acid, flow rate of 3.0 mL / min, and elution time of 30 min, to obtain fraction Fr.D-1.
[0016] (3) The component Fr.D-1 was further separated and purified by semi-preparative high performance liquid chromatography (HPLC) using a Polaris semi-preparative column. The mobile phase was 23% acetonitrile aqueous solution containing 0.001% formic acid, the flow rate was 3.0 mL / min, the eluent with a retention time of 15.9 min was collected to obtain compound L53, and the eluent with a retention time of 18.4 min was collected to obtain compound L56.
[0017] A third object of the present invention is to provide an antibacterial composition comprising compound L53 and / or compound L56 as active ingredients, and agriculturally acceptable carriers and adjuvants.
[0018] A fourth objective of this invention is to provide the use of the above-mentioned natural antibacterial compounds or antibacterial compositions in the preparation of agents for inhibiting plant pathogens.
[0019] Preferably, the compound works by disrupting the integrity of the sporangium plasma membrane of pathogenic fungi, increasing cell membrane permeability, and reducing intracellular...
[0020] It reduces ATP content and inhibits mycelial respiration and metabolism, thereby inhibiting the growth of pathogenic mycelia and sporangium germination.
[0021] Preferably, when the active ingredient is compound L53, the plant pathogen includes Phytophthora lichee (…). Peronophythora litchii Fusarium oxysporum ( Fusarium oxysporum f. sp. cubense ), Pseudomonas syringae ( Pseudomonas syringae Xanthomonas aeruginosa (), Xanthomonas campestris pv. badrii ), Tomato Ralstonia solanacearum ( Ralstonia solanacearum ).
[0022] Preferably, when the active ingredient is compound L56, the plant pathogen includes Phytophthora lichee (…). Peronophythora litchii Fusarium oxysporum ( Fusarium oxysporum f. sp. cubense ), Pseudomonas syringae ( Pseudomonas syringae Xanthomonas aeruginosa (), Xanthomonas campestris pv. badrii ), Citrus canker pathogen ( Xanthomonas citri subsp. citri ), Tomato Ralstonia solanacearum ( Ralstonia solanacearum ).
[0023] The fifth objective of this invention is to provide a method for preventing and controlling plant diseases, comprising the following steps: applying an effective amount of compound L53 and / or L56, or an agent containing compound L53 and / or L56, to plants infected by the aforementioned plant pathogens.
[0024] The results of the antibacterial activity studies of compounds L53 and L56 in this invention show that compound L53 has a high inhibition rate of 74.67% on the mycelial growth of Phytophthora litchii and can significantly inhibit the germination of sporangia of Phytophthora litchii. It exerts its antibacterial effect through multiple pathways, such as disrupting the integrity of the pathogen's plasma membrane, inducing intracellular electrolyte leakage, reducing intracellular ATP content, and inhibiting mycelial respiration and metabolism. Compound L56 also has a significant inhibitory effect on the mycelial growth and sporangia germination of Phytophthora litchii, but its activity against Phytophthora litchiii is weaker than that of compound L53.
[0025] Regarding broad-spectrum antibacterial activity, the two compounds exhibited significant differences in their antibacterial spectrum. Compound L53 showed significant inhibitory activity against *Fusarium oxysporum*, and also inhibited *Pseudomonas syringae*, *Xanthomonas campestris*, and *Ralstonia solanacearum*, but had no significant inhibitory effect on *Ralstonia solanacearum*. Compound L56 possessed excellent anti-oomycete, antifungal, and broad-spectrum antibacterial activities, showing significant inhibitory effects against *Fusarium oxysporum*, *Pseudomonas syringae*, *Xanthomonas campestris*, *Ralstonia solanacearum*, and *Ralstonia solanacearum*. Both compounds showed significant antibacterial effects against *Phytophthora licheniformis* with a clear mechanism of action, possessing extremely high value for the development of green pesticides.
[0026] Compared with the prior art, the present invention has the following beneficial effects:
[0027] 1. L53 and L56 are novel nitrogen-containing compounds that were isolated and identified from natural sources for the first time in this invention. No structural information of the above compounds has been disclosed in the prior art, nor has any related content of the above compounds been reported.
[0028] 2. This invention is the first to discover that compounds L53 and L56 have significant inhibitory activity against Phytophthora litchii, and for the first time confirms the inhibitory use of the above two novel structural compounds against plant pathogenic fungi, filling the technological gap in the research and development of novel natural lead compounds for Phytophthora litchii.
[0029] 3. This invention elucidates the antibacterial mechanism of compounds L53 and L56 through a multi-dimensional experimental system, confirming that they exert their antibacterial effect through multiple pathways, including disrupting the integrity of pathogen cell membranes, inducing electrolyte leakage, interfering with ATP energy metabolism, inhibiting respiratory metabolism, and disrupting cell ultrastructure. The theoretical basis is sufficient and the mechanism is clear.
[0030] 4. Compounds L53 and L56 can be used alone as active ingredients in the preparation of pesticide formulations for the control of plant diseases, mainly for the green control of lychee downy mildew, while also exhibiting inhibitory effects on various fungal and bacterial plant diseases. Compared with existing technologies, this invention overcomes the technical defects of existing biological control materials for lychee downy mildew, such as insufficient activity, unclear mechanism of action, single structural type, and narrow antibacterial spectrum, and has good prospects for industrial application.
[0031] The salt-tolerant short-spore bacillus of the present invention ( Brevibacillus halotolerans T101 was deposited on July 23, 2025 at the Guangdong Provincial Microbial Culture Collection Center (GDMCC), located at 5th Floor, Building 59, No. 100 Xianlie Middle Road, Yuexiu District, Guangzhou, Guangdong Province, 510070, China. Its accession number is GDMCC No. 66731. Attached Figure Description
[0032] Figure 1 It is compound L53 1 H NMR spectrum.
[0033] Figure 2 It is compound L53 1 C NMR spectrum.
[0034] Figure 3 This is the HR-ESI-MS spectrum of compound L53.
[0035] Figure 4 It is compound L56 1 H NMR spectrum.
[0036] Figure 5 It is compound L56 1 C NMR spectrum.
[0037] Figure 6 This is the HR-ESI-MS spectrum of compound L56.
[0038] Figure 7These are the chemical structural formulas of compounds L53 and L56.
[0039] Figure 8 The results show the inhibitory activity of compounds L53 and L56 against Phytophthora lichei.
[0040] Figure 9 The results show the inhibition of sporangium germination by compounds L53 and L56 on Phytophthora lichee.
[0041] Figure 10 The effect of compounds L53 and L56 on sporangium membrane integrity was detected by PI staining.
[0042] Figure 11 The changes in ATP content of Phytophthora downy mildew mycelia after treatment with compounds L53 and L56 are shown.
[0043] Figure 12 This represents the dynamic changes in mycelial respiration rate after treatment with compounds L53 and L56.
[0044] Figure 13 The change in hyphal conductivity after treatment with compounds L53 and L56 is shown.
[0045] Figure 14 This is a SEM image of the ultrastructure of Phytophthora sporangia treated with L53 on litchi.
[0046] Figure 15 These are the results of the broad-spectrum antibacterial activity assay for compounds L53 and L56. Detailed Implementation
[0047] The present invention will be further explained below with reference to the embodiments, but the embodiments do not limit the present invention in any way.
[0048] Example 1: Preparation and structural identification of compounds L53 and L56
[0049] 1. The salt-tolerant short-spore bacillus of the present invention ( Brevibacillus halotolerans T101 was deposited on July 23, 2025 at the Guangdong Provincial Microbial Culture Collection Center (GDMCC), located at 5th Floor, Building 59, No. 100 Xianlie Middle Road, Yuexiu District, Guangzhou, Guangdong Province, 510070, China. Its accession number is GDMCC No. 66731.
[0050] 2. Salt-tolerant short-spore bacteria ( Brevibacillus halotoleran s) Liquid fermentation of T101
[0051] The T101 glycerol strain was activated in TSA medium and cultured upside down at 30°C for 2 days. A single colony of the freshly activated strain was picked and inoculated into a test tube containing TSB medium. The tube was then shaken at 200 rpm for 24 hours at 30°C to obtain the T101 seed culture. This seed culture was then transferred to TSB medium at a 1% (v / v) inoculum for propagation to obtain the T101 bacterial culture. For large-scale fermentation, the bacterial culture was transferred to 20 L of TSB medium at a 10% (v / v) inoculum and fermented at 30°C and 200 rpm for 9 days to obtain the liquid fermentation culture.
[0052] TSA agar medium (g / L): tryptone 15.0, soybean peptone 5.0, sodium chloride 5.0, agar 15, using distilled water (purified water) as solvent. TSB medium is TSA medium without added agar.
[0053] 3. Preparation of compounds
[0054] (1) Extraction of salt-tolerant short-spore bacilli using macroporous adsorption resin XAD-16 ( Brevibacillus halotoleran s) One hour before the end of fermentation, activated XAD-16 resin was added to the liquid fermentation culture of strain T101 at a concentration of 3% (w / v) for adsorption. After fermentation, the culture was filtered through gauze to obtain macroporous resin containing secondary metabolites of strain T101 and a small amount of bacterial cells, which were then air-dried in a ventilated place. The dried macroporous resin was then added to 10 times its volume of methanol solution and extracted by shaking in a shaker at 200 rpm for 1 day. The extract was concentrated to obtain approximately 39 g of extract.
[0055] (2) The extracts were separated by normal silica gel column chromatography. Petroleum ether-ethyl acetate (volume ratio of 10:1, 5:1, 2:1, 1:1, 1:2, 0:1), ethyl acetate-methanol (volume ratio of 30:1, 20:1, 15:1, 10:1, 5:1, 0:1), and pure methanol were used as eluents. Approximately 2-3 L of the separation solution was used for each concentration gradient. The components with different proportions of eluents were collected, rotary evaporated, eluted with methanol, and packed into small test tubes and numbered in sequence. A portion was taken for thin-layer chromatography (TLC) plate development. The same components were combined by TLC results. Fr.D was synthesized from the fraction eluted with ethyl acetate-methanol (15:1). The fraction Fr.D was then separated and purified by high performance liquid chromatography (mobile phase: 49% acetonitrile aqueous solution containing 0.001% formic acid; elution time: 30 min; flow rate: 3.0 mL / min; YMC semi-preparative column) to obtain fraction Fr.D-1 (223.1 mg).
[0056] (3) Component Fr.D-1 was separated and purified by high performance liquid chromatography using a Polaris semi-preparative column. The mobile phase was 23% acetonitrile aqueous solution (containing 0.001% formic acid), the flow rate was 3.0 mL / min, and the eluent fraction with a retention time of 15.9 min was collected to obtain compound L53 (2 mg). The eluent fraction with a retention time of 18.4 min was collected to obtain compound L56 (2 mg).
[0057] 4. Structural identification of compounds
[0058] NMR spectra were determined using a Bruker Ascend™ 400M NMR spectrometer, with tetramethylsilane (TMS) as an internal standard; HR-ESI-MS data were determined using a Thermo Fisher Orbitrap Exploris 120 high-resolution liquid chromatography-mass spectrometry system. The structural identification data are as follows:
[0059] like Figure 1-6 As shown, Figure 1 It is compound L53 1 H NMR spectrum; Figure 2 It is compound L53 1 C NMR spectrum; Figure 3 This is the HR-ESI-MS spectrum of compound L53; Figure 4 It is compound L56 1 H NMR spectrum; Figure 5 It is compound L56 1 C NMR spectrum; Figure 6 This is the HR-ESI-MS spectrum of compound L56.
[0060] The characterization data of the new compounds L53 and L56 are as follows:
[0061] HR-ESI-MS (m / z) of compound L53: 386.2308 [M+H] + C 23 H 31 NO4, calculated value is 386.2326.
[0062] HR-ESI-MS (m / z) of compound L56: 428.2781 [M+H] + C 26 H 37 NO4, calculated value is 428.2795.
[0063] The structural formulas and NMR data of compounds L53 and L56 are shown in Table 1:
[0064] Table 1. Compounds L53 and L561 H and 13 C NMR data (δ in ppm, J in Hz, CDCl3)
[0065] The structural formulas of the target compounds L53 and L56 separated by the above method are as follows: Figure 7 As shown.
[0066] Example 2: Antifungal activity and antifungal mechanism of new compounds L53 and L56 against Phytophthora licoricei.
[0067] 1. Inhibitory effect of the compound on the mycelial growth of Phytophthora licheniformis.
[0068] The compound was dissolved in DMSO to prepare a 5 mg / mL stock solution. The antifungal activity of the compound against *Phytophthora lichei* was determined in 6-well plates using the toxic agar plate method: the compound or sterile water (control) was added to R2A medium to a final concentration of 100 μg / mL; a 4 mm diameter mycelial cake was placed in the center of the 6-well plate and incubated at 25°C for 3 days. Mycelial growth was observed and mycelial diameter was measured to calculate the inhibition rate. Growth inhibition rate (%) = (control group mycelial diameter - treatment group mycelial diameter) / (control group mycelial diameter - 4 mm) × 100%.
[0069] The results showed that compound L53 inhibited the growth of *Phytophthora licoricei* mycelium by 74.67%, while L56 inhibited it by 63.99%. Figure 8 ).
[0070] 2. Effects of compounds on the germination of sporangia of Phytophthora lichee
[0071] A 100 μg / mL compound was mixed with a suspension of *Phytophthora lichei* sporangia at a 1:1 (v / v) ratio and incubated at 28 °C for 4 h. A portion of the sample was then examined under an optical microscope to observe the morphology of the *Phytophthora lichei* sporangia and to count the number of germinating sporangia.
[0072] The results showed that both compounds L53 and L56 treatments could inhibit the germination of sporangia of Phytophthora lichei. Specifically, the sporangia germination rate after L53 treatment was only 13.87%, while the sporangia germination rate after L56 treatment was 19.27%. Figure 9 This indicates that both methods can block the spread of disease from the source of reproduction.
[0073] 3. Integrity of the plasma membrane of Phytophthora litchifolia after compound treatment
[0074] Suspensions of *Phytophthora lichee* sporangia were treated with a compound at a final concentration of 100 μg / mL, with sterile water treatment serving as a control. After staining with 8 mg / L propidium iodide (PI) and incubation for 10 min, the sporangia were washed three times with PBS. The sporangia were observed using a fluorescence biological microscope in both bright-field and fluorescence channels, and the number of sporangia was counted. Each group was divided into three biological replicates, with nine fields of view randomly selected in each replicate.
[0075] PI staining results showed that both compounds severely damaged the sporangium plasma membrane; the integrity rate of the plasma membrane in the L53 treatment group decreased to 37.08%, and the integrity rate in the L56 treatment group decreased to 61.94%. Figure 10 ).
[0076] 4. Analysis of the effects of compound treatment on ATP content, respiration rate and conductivity of Phytophthora lichee mycelia
[0077] ATP content determination of mycelia: 10 μL of *Phytophthora lichei* sporangium suspension was added to either the compound or sterile water (control group) to a final concentration of 100 μg / mL. After incubation at 25℃ for 6 and 12 h, 0.5 g of mycelium was collected, centrifuged at 10000 g at 4℃ for 10 min, and the supernatant was collected into another EP tube. The ATP content of *Phytophthora lichei* mycelia was determined using an ATP content assay kit. Each treatment at each sampling time had three replicates, and each replicate of mycelia was obtained from one sporangium suspension.
[0078] To determine the effect of the compound on mycelial respiration rate, 1 mL of sporangium suspension was added to either the compound or sterile water (control) to achieve a final concentration of 100 μg / mL. The respiration rate was measured using a portable dissolved oxygen analyzer. Mycelial oxygen consumption was recorded over 2 hours at 0, 5, 10, 20, 40, 60, 80, 100, and 120 min. The respiration rate was expressed as μmol·g⁻¹. -1 ·h -1 This indicates that each treatment at each time point consists of 3 repetitions.
[0079] Mycelial conductivity determination: 0.5 g of Phytophthora lichee mycelia were weighed, ground, and dissolved in sterile water. A compound (sterile water control) was added to bring the final concentration to 100 μg / mL. After thorough mixing, the mixture was incubated at 28℃ and 180 rpm. The conductivity of the mycelia was measured at 0, 5, 10, 20, 40, 60, 80, 100, and 120 min using a conductivity meter. Each treatment at each time point consisted of three replicates.
[0080] The results showed that after treatment with both compounds, the intracellular ATP content and respiration rate of *Phytophthora licheniformis* hyphae decreased significantly, intracellular electrolytes leaked in large quantities, and cell membrane permeability increased dramatically. Figure 11 , Figure 12 , Figure 13 ).
[0081] 5. Observation of the ultrastructure of compounds
[0082] The edges of the compound-treated Phytophthora downy mildew hyphae were removed using a blade. The samples were first fixed with 3% glutaraldehyde for 24 h, then washed six times with 0.1 mol / L PBS (pH 7.0) for 20 min each time. Subsequently, they were dehydrated twice each with 30% ethanol and 50% ethanol for 10 min each time. Finally, they were treated overnight with 70% ethanol at 4°C. Afterwards, they were dehydrated twice with 90% ethanol for 15 min each time, followed by three times with anhydrous ethanol for 15 min each time. Subsequent procedures, including sample transfer, replacement, heating, and degassing, were performed in the electron microscopy room.
[0083] Scanning electron microscopy revealed that the sporangia of Phytophthora litica treated with L53 were generally shrunken and collapsed, with damaged cell structure. Figure 14 ).
[0084] Example 3: Determination of the antibacterial spectrum of new compounds L53 and L56
[0085] To clarify the antibacterial spectrum of the compound, the pathogenic fungus *Fusarium oxysporum* was selected. Fusarium oxysporum f.sp. cubense Foc4) and four plant pathogenic bacteria: *Pseudomonas syringae* (Foc4) and four plant pathogenic bacteria. Pseudomonas syringae GDMCC1.330), Xanthomonas oryzae ( Xanthomonas campestris badrii JCM 20466), Tomato Ralstonia solanacearum ( Ralstonia solanacearum GMI 1000) and citrus canker pathogen ( Xanthomonas citri subsp. citri XCC conducted antibacterial tests.
[0086] The antibacterial activity of the compound against *Fusarium oxysporum* was determined using the toxic plate method, the same as the activity determination against *Phytophthora licoricei* in step 1 of Example 2 above. The antibacterial activity of the compound against plant pathogenic bacteria was determined using the micro-broth dilution method. The experiment was conducted using 96-well plates, and the absorbance (OD) at 600 nm was measured using a microplate reader. 600 The number of viable bacteria was inferred based on the optical density (OD) value. The test compound was mixed with suspensions of four pathogens—*Pseudomonas syringae*, *Xanthomonas spp.*, *Ralstonia solanacearum*, and *Ralstonia solanacearum*—in a 96-well sterile plate containing TSB liquid medium (OD values were used to estimate the number of viable bacteria). 600 Mix 0.05-0.1 g of the solution and adjust the final concentration to 100 μg / mL. Incubate at 30°C for 24 h, observe bacterial growth, and measure OD200. 600 All antibacterial tests were performed in triplicate.
[0087] The results of the toxic plate test showed that both L53 and L56 at 100 μg / mL significantly inhibited the mycelial growth of Fusarium oxysporum Foc4; L53 had a stronger inhibitory effect, with a mycelial growth inhibition rate of 42.42%, while L56 had an inhibition rate of 39.12%. Figure 15 Micro-broth dilution experiments showed that both L53 and L56 significantly inhibited the growth of *Pseudomonas syringae* and *Ralstonia solanacearum*; L53 significantly inhibited the growth of *Xanthomonas scabra*, while L56 had a weaker inhibitory effect on *Xanthomonas scabra*; regarding *Citrus canker*, there was no significant difference between the L53 treatment group and the control group, showing no obvious inhibitory activity, while L56 showed a significant inhibitory effect. Figure 15 In summary, the two bacteria exhibit significant differences in their antibacterial spectra. L53 can inhibit Fusarium oxysporum, Pseudomonas syringae, Xanthomonas spp., and Ralstonia solanacearum, but has no inhibitory effect on citrus canker pathogens. L56 possesses both antifungal and broad-spectrum antibacterial activities, showing inhibitory effects against Fusarium oxysporum and the four tested pathogens.
[0088] The above description of the embodiments is only for the purpose of helping to understand the technical solution and core idea of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications also fall within the protection scope of the claims of the present invention.
Claims
1. A natural antibacterial compound, characterized in that, The compound is compound 2 as shown in formula (I). E -Basiliskamide B or the compound Basiliskamide C shown in formula (II): 。 2. A method for preparing the natural antibacterial compound as described in claim 1, characterized in that, Compound 2 E -Basiliskamide B and Basiliskamide C were isolated from salt-tolerant Bacillus brevis ( Brevibacillus halotolerans T101 fermentation metabolites.
3. The preparation method according to claim 2, characterized in that, Specifically, the following steps are included: (1) To Brevibacillus halotolerans T101 was subjected to liquid fermentation culture, and the fermentation broth was collected; (2) The fermentation broth was enriched using macroporous resin to obtain total metabolic extract; (3) The extract was purified by silica gel column chromatography and reversed-phase high performance liquid chromatography to obtain monomeric compounds 2E-Basiliskamide B or Basiliskamide C.
4. The preparation method according to claim 3, characterized in that, In step (2), the macroporous resin is XAD-16 resin; the enrichment treatment includes: passing the fermentation broth through an XAD-16 resin column for adsorption, filtering and collecting the adsorbed resin and drying it, adding 8 to 12 times the volume of methanol solution to the dried resin, shaking and extracting it in a shaker at 180 to 220 rpm for 20 to 30 h, collecting the extract and concentrating it to obtain the total metabolic extract.
5. The preparation method according to claim 3, characterized in that, In step (3), the silica gel column chromatography employs gradient elution, with the following elution systems in sequence: petroleum ether-ethyl acetate volume ratios of 10:1, 5:1, 2:1, 1:1, 1:2, and 0:1, and ethyl acetate-methanol volume ratios of 30:1, 20:1, 15:1, 10:1, 5:1, and 0:1, followed by elution with pure methanol. The volume of solvent used for each gradient elution is 2-3 L. The fraction eluted with ethyl acetate-methanol at a volume ratio of 15:1 is collected and named Fr.D.
6. The preparation method according to claim 3, characterized in that, In step (3), the reversed-phase high-performance liquid chromatography (RP-HPLC) separation and purification includes the following steps: The component Fr.D is initially separated using semi-preparative HPLC under the following chromatographic conditions: YMC semi-preparative column, mobile phase is 49% acetonitrile aqueous solution containing 0.001% formic acid, flow rate is 3.0 mL / min, elution time is 30 min, to obtain component Fr.D-1; Component Fr.D-1 is further separated and purified by semi-preparative HPLC using a Polaris semi-preparative column, mobile phase is 23% acetonitrile aqueous solution containing 0.001% formic acid, flow rate is 3.0 mL / min; the eluted component with a retention time of 15.9 min is collected to obtain compound 2E-Basiliskamide B, and the eluted component with a retention time of 18.4 min is collected to obtain compound Basiliskamide C.
7. An antibacterial composition, characterized in that, It comprises the compounds 2E-Basiliskamide B and / or Basiliskamide C as active ingredients as described in claim 1, as well as agriculturally acceptable carriers and adjuvants.
8. The use of the natural antibacterial compound of claim 1 or the antibacterial composition of claim 7 in the preparation of agents for inhibiting plant pathogens.
9. The application according to claim 8, characterized in that, When the active ingredient is compound 2 E When -Basiliskamide B is used, the plant pathogens include Phytophthora licheeensis ( Peronophythora litchii Fusarium oxysporum ( Fusarium oxysporum f. sp. cubense ), Pseudomonas syringae ( Pseudomonas syringae Xanthomonas aeruginosa (), Xanthomonas campestris pv. badrii ), Tomato Ralstonia solanacearum ( Ralstonia solanacearum ); When the active ingredient is the compound Basiliskamide C, the plant pathogen includes Phytophthora lichee (…). Peronophythora litchii Fusarium oxysporum ( Fusarium oxysporum f. sp. from Cuba ), Pseudomonas syringae ( Pseudomonas syringae Xanthomonas aeruginosa (), Xanthomonas campestris pv. bad ), Citrus canker pathogen ( Xanthomonas citri subsp. lemons ), Tomato Ralstonia solanacearum ( Ralstonia nightshade ).
10. A method for preventing and controlling plant diseases, characterized in that, The effective amount of compound 2 E -Basiliskamide B and / or Basiliskamide C, or containing compound 2 E - An agent of Basiliskamide B and / or Basiliskamide C, applied to plants infected with the plant pathogen of claim 9.
